Inhibition of microsomal lipid peroxidation and cytochrome P-450-catalyzed reactions by nitrofuran compounds.
(5-Nitro-2-furfurylidene)amino compounds bearing triazol-4-yl, benzimidazol-1-yl, pyrazol-1-yl, triazin-4-yl or related groups (a) stimulated superoxide anion radical generated by rat liver microsomes in the presence of NADPH and oxygen; (b) inhibited the NADPH-dependent, iron-catalyzed microsomal lipid peroxidation; (c) prevented the NADPH-dependent destruction of cytochrome P-450; (d) inhibited the NADPH-dependent microsomal aniline 4-hydroxylase activity; (e) failed to inhibit either the cumenyl hydroperoxide-dependent lipid peroxidation or the aniline-4-hydroxylase activity, except for the benzimidazol-1-yl and the substituted triazol-4-yl derivatives, which produced minor inhibitions. Reducing equivalents enhanced the benzimidazol-1-yl derivative inhibition of the cumenyl hydroperoxide-induced lipid peroxidation. The ESR spectrum of the benzimidazol-1-yl derivative, reduced anaerobically by NADPH-supplemented microsomes, showed characteristic spin couplings. Compounds bearing unsaturated nitrogen heterocycles were always more active than those bearing other groups, such as nifurtimox or nitrofurazone. The energy level of the lowest unoccupied molecular orbital was in fair agreement with the capability of nitrofurans for redox-cycling and related actions. It is concluded that nitrofuran inhibition of microsomal lipid peroxidation and cytochrome P-450-catalyzed reactions was mostly due to diversion of reducing equivalents from NADPH to dioxygen. Trapping of free radicals involved in propagating lipid peroxidation might contribute to the overall effect of the benzimidazol-1-yl and substituted triazol-4-yl derivatives.
Dubin
M
M
Centro de Investigaciones Bioenergéticas, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
Fernandez Villamil
S H
SH
Paulino de Blumenfeld
M
M
Stoppani
A O
AO
D000815:Aniline Hydroxylase / Q000037:antagonists & inhibitors; D000818:Animals; D065607:Cytochrome P-450 Enzyme Inhibitors; D004578:Electron Spin Resonance Spectroscopy; D007501:Iron / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects*; D008099:Liver; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D008861:Microsomes / Q000187:drug effects* / Q000378:metabolism; D009249:NADP / Q000378:metabolism; D009547:Nifurtimox / Q000031:analogs & derivatives / Q000494:pharmacology; D009581:Nitrofurans / Q000494:pharmacology*; D010084:Oxidation-Reduction; D010100:Oxygen / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013481:Superoxides / Q000378:metabolism
D065607:Cytochrome P-450 Enzyme Inhibitors; D009581:Nitrofurans; D013481:Superoxides; D008315:Malondialdehyde; D009249:NADP; D007501:Iron; D000815:Aniline Hydroxylase; D009547:Nifurtimox; D010100:Oxygen